Clinical trial
A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells.
NCT00499018 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells.
- Lead sponsor
- Fondazione Italiana Linfomi - ETS
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 31, 2006
- Completion date
- September 30, 2013
- Enrollment
- 399 (estimated)
- Sites
- 75
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b-cell lymphoma, ipi≥2